Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 41.5% from a year ago
Total equity stood at $2.49M at the end of Q1 FY2026, down 41.5% from a year earlier and down 45.5% from the prior quarter.
Context
- Total equity amounted to 71.0% of total assets at the end of Q1 FY2026, down 24.8 pp from a year earlier.
- Total equity increased in 1 of the last 2 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -41.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 4.57M USD
- Year-over-year change
- -3.1%
- 2-year CAGR
- +89.1%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.57M | -3.1% |
| FY2024 | 2024-12-31 | 4.71M | +269.0% |
| FY2023 | 2023-12-31 | 1.28M | — |
Total Equity vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's Mar 2026 total equity of $2.49M is the 7th highest of the 8 companies compared; the peer median is $81.76M.
- Its year-over-year change of -41.5% is the lowest of 8, against a peer median of +11.5%.
- Total equity amounts to 71.0% of total assets for PLYX, versus a peer median of 78.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $296.46M | +295.0% | +37.9% | 92.8% | |
| Mar 2026 | $273.67M | -18.7% | -33.2% | 78.1% | |
| Mar 2026 | $183.85M | +5346.9% | +67.8% | 92.3% | |
| Mar 2026 | $81.76M | +11.5% | -17.8% | 93.4% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $68.56M | +7.3% | — | 62.4% |
| Mar 2026 | $35.1M | +936.6% | — | 24.1% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | Mar 2026 | $2.49M | -41.5% | — | 71.0% |
| Mar 2026 | -$76.41M | -23.9% | — | 34.4% | |
| Peer median (excluding PLYX) | $81.76M | +11.5% | +10.1% | 78.1% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Cash & Equivalents | 2K | 4.62M | 5.14M |
| Short-term Investments | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 27K |
| Total Current Assets | 2.32M | 5M | 5.17M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 250K |
| Other Non-current Assets | 0 | 0 | 0 |
| Total Non-current Assets | 0 | 0 | 250K |
| Total Assets | 2.32M | 5M | 5.42M |
| Account Payables | 473K | 72K | 470K |
| Short-term Debt | 128K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 |
| Other Current Liabilities | 1K | 1K | 114K |
| Total Current Liabilities | 1.04M | 289K | 605K |
| Long-term Debt | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 250K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 250K |
| Total Liabilities | 1.04M | 289K | 855K |
| Common Stock | 4K | 16K | 5K |
| Retained Earnings | (60.29M) | (90.65M) | (99.64M) |
| Accumulated OCI | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Total Equity | 1.28M | 4.71M | 4.57M |
| Total Debt | 128K | 0 | 0 |
| Net Debt | 126K | (4.62M) | (5.14M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.